Evidence map›Paper›PMID 37256137›Full record

ArticleFrontiers in immunology2023

Omicron (B.1.1.529) BA.1 or BA.2-related effects on immune responses in previously naïve versus imprinted individuals: immune imprinting as an advantage in the humoral immune response against novel variants.

Sissy Therese Sonnleitner, Samira Walder, Ludwig Knabl, Roswitha Poernbacher, Thomas Tschurtschenthaler, Eva Hinterbichler, Stefanie Sonnleitner, Viktoria Muehlmann, Wilfried Posch, Gernot Walder

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Sissy Therese SonnleitnerDepartment of Virology, Medical Laboratory, Dr. Gernot Walder GmbH, Ausservillgraten, Austria.
Samira WalderDepartment of Virology, Medical Laboratory, Dr. Gernot Walder GmbH, Ausservillgraten, Austria.
Ludwig KnablInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Roswitha PoernbacherDepartment of Virology, Medical Laboratory, Dr. Gernot Walder GmbH, Ausservillgraten, Austria.
Thomas TschurtschenthalerDepartment of Virology, Medical Laboratory, Dr. Gernot Walder GmbH, Ausservillgraten, Austria.
Eva HinterbichlerDepartment of Virology, Medical Laboratory, Dr. Gernot Walder GmbH, Ausservillgraten, Austria.
Stefanie SonnleitnerDepartment of Virology, Medical Laboratory, Dr. Gernot Walder GmbH, Ausservillgraten, Austria.
Viktoria MuehlmannDepartment of Virology, Medical Laboratory, Dr. Gernot Walder GmbH, Ausservillgraten, Austria.
Wilfried PoschInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Gernot WalderDepartment of Virology, Medical Laboratory, Dr. Gernot Walder GmbH, Ausservillgraten, Austria.
Voestalpine (Austria) · ATUniversität Innsbruck · ATInnsbruck Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune imprinting is a phenomenon in which a person's immune system develops a specific immunological memory of the pathogen or vaccine due to a previous exposure. This memory basically leads to a faster and stronger immune response in a subsequent contact to the same pathogen or vaccine. However, what happens if the pathogen has changed considerably in the meantime due to mutations in the main target region of antibodies, as in the evolution of SARS-CoV-2 from the ancestral strain to B.1.1.529 (Omicron)? In this case, does immune imprinting also confer an advantage in repeated contact and does it lead to a stronger immune response? Methods: To clarify these questions, we investigated the effects of immune imprinting in the context of SARS-CoV-2 by comparing a group of previously infection-naïve versus imprinted study participants and determined differences in humoral and cellular immune responses during and after infection with strain SARS-CoV-2 B.1.1.529 BA.1 and BA.2, respectively. We used a commercial CLIA, immunoblots, IFN-γ ELISpots and a plaque-reduction neutralization test to generate a clear and comparable picture of the humoral and cellular immune response in the two study groups. Results: Imprinted participants developed significantly higher antibody titers and showed significantly stronger neutralization capacity against the ancestral strain, BA.1 and BA.5. The immune response of naïve study participants was narrower and related mainly to the receptor-binding domain, which resulted in a lower neutralization capacity against other strains including BA.5. Naïve study participants showed a significantly higher cellular immune response than the imprinted study group, indicating a higher antigenic challenge. The cellular immune response was directed against general structures of SARS-CoV-2 and not specifically against the receptor-binding domain. Conclusion: Viral variant infection elicits variant-specific antibodies and prior mRNA vaccination or infection with a previous SARS-CoV-2 variant imprints serological responses toward the ancestral strain rather than variant antigens. On the other hand, our study shows that the initially higher specific antibody titers due to former imprinting via vaccination or prior infection significantly increased the humoral immune response, and therefore outperformed the humoral immune response of naïve study participants.

Indexed as

COVID-19Immunity, HumoralAntibodiesHumansSARS-CoV-2AntibodiesB.1.1.529ELISpotimmune response to omicron infectionnaïve versus imprintedomicron infectionSARS-CoV-2serology

Identifiers

PMID37256137
PMCPMC10225645
OpenAlexW4376609758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.